Phase 1Data readout

IMA401/IMA402 (TCR Bispecific Combination)

Squamous Non-Small Cell Lung Cancer

IMTXImmatics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: IMA401/IMA402 (TCR Bispecific Combination)
Development stage: Phase 1
Event type: Data readout
Indication: Squamous Non-Small Cell Lung Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for IMA401/IMA402 (TCR Bispecific Combination) in Squamous Non-Small Cell Lung Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

05/31/26:- Combination cohort enrolling in sqNSCLC; first Phase 1 data expected 2027. 08/18/26:- Phase 1b sqNSCLC combination cohort is enrolling. First data is expected in 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

IMA401/IMA402 (TCR Bispecific Combination)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

ACTengine® IMA203 GEN1 (PRAME)

TCER® IMA402 (PRAME)

ACTengine® IMA203CD8 GEN2 (PRAME)

ACTengine® IMA203CD8 GEN2 (PRAME)